---
title: Is Mounjaro or Ozempic Better for Losing Weight? Complete Comparison Guide
date: '2026-07-21'
slug: is-mounjaro-or-ozempic-better-for-losing-weight-complete-comparison-guide
description: Compare Mounjaro vs Ozempic for weight loss. See trial results, real‑world
  outcomes, and which GLP‑1 may deliver more pounds off.
updated: '2026-07-21'
author: Dr. Benjamin Paul
site: 'Pepio: GLP-1 Peptide Tracker'
---

# Is Mounjaro or Ozempic Better for Losing Weight? Complete Comparison Guide

## Why Compare Mounjaro and Ozempic for Weight Loss?

If you searched for the best GLP-1 weight loss comparison guide, this piece gives a practical, evidence-based view. Headlines show larger weight loss with Mounjaro than with Ozempic. Recent analyses report larger average loss with tirzepatide (Mounjaro) than semaglutide (Ozempic) over similar follow-up durations. Real-world reports note similar gaps between the drugs ([Los Angeles Times](https://www.latimes.com/science/story/2024-07-08/mounjaro-bests-ozempic-for-weight-loss); [Clinicaeupnea](https://clinicaeupnea.com/en/blog/ozempic-vs-mounjaro-comparison/)). Numbers matter, but they are only part of the decision. We use a six-factor framework to compare outcomes, side effects, access, dosing schedule, cost, and personal goals. Each factor weighs differently depending on your priorities and coverage. This guide stays practical, not prescriptive, and focuses on what to track as you decide. Pepio helps you record dose dates, symptoms, weight, and injection sites so comparisons are based on clear records. Users using Pepio bring organized notes to clinician visits and avoid relying on memory.

## Comparison Criteria: What to Evaluate When Choosing a GLP‑1

Track these criteria when you compare Mounjaro and Ozempic. Tools like Pepio help you collect the exact data needed to assess real-world differences between options.

- Average percent body weight loss in clinical trials How much weight a drug typically reduces matters for expectations. Trials show GLP‑1/GIP and GLP‑1 agents commonly produce about 5%–15% body‑weight loss, with higher doses often reaching the top of that range ([PMCID 11404059](https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/)).
- Time to see measurable change When weight change begins and when it peaks affects patience and planning. Measurable reductions often start at 4–6 weeks, with peak effects around 24–36 weeks in many trials ([PMCID 11404059](https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/)).

- Weekly vs daily dosing flexibility Dosing cadence can affect adherence and lifestyle fit. Weekly injectables and daily oral options differ in convenience, timing, and how missed doses impact your routine (see practical overviews in [Drugs.com](https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/) and clinical summaries).
- Common side‑effects and severity Expect nausea, vomiting, and constipation to be the most frequent side effects. Rates vary, but nausea occurs in roughly 30%–45% of users, vomiting in about 10%–15%, and serious events remain uncommon ([RAND Report](https://www.rand.org/pubs/research_reports/RRA4153-1.html)).

- Injection‑site rotation needs For injectables, rotating sites reduces lipohypertrophy risk and improves comfort. Weekly regimens lower rotation frequency compared with daily injections, a practical point clinicians and users note ([UpToDate](https://www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus)).
- How a tracker like Pepio can capture these data points A structured tracker collects dose dates, weight trends, symptom timing, and site history. Consolidated logs make side‑by‑side comparisons and clinician conversations easier ([Pharmaceutical Journal](https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-glp-1s-for-weight-loss-2)).

- Log each injection and dose
- Track weekly weight and symptom trends. Pepio logs dose dates and injection sites, with exportable summaries for clinician visits.
- Export reports for clinician visits

Pepio helps you keep dose dates, injection sites, symptoms, and weight in one record. Users who track engagement often see clearer trend lines; digital engagement links to improved monitoring and follow‑up ([impact study](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997532/)). You can find Pepio listed as a GLP‑1 tracker on the App Store for quick reference ([Pep GLP‑1 Tracker on the App Store](https://apps.apple.com/us/app/glp-1-tracker-pep-glp1/id6504788281)). Pepio's approach makes it easier to compare real outcomes without guessing.

Pepio is for organization and self‑tracking only. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. Learn more about Pepio’s approach to organizing GLP‑1 routines as you weigh treatment options.

## Option 1 – Pepio GLP‑1 & Peptide Tracker (Recommended Choice)

Pepio GLP-1 tracker benefits for weight loss decisions: Pepio consolidates dose, site, symptom, and weight data so you can spot patterns when comparing Mounjaro and Ozempic. The app’s listing highlights that users keep all routine details in one place, reducing scattered notes and spreadsheets ([Pep GLP-1 Tracker – App Store](https://apps.apple.com/us/app/glp-1-tracker-pep-glp1/id6504788281)). This organized view helps you and your clinician discuss real-world progress, not guesswork. Pepio’s web tools are free, no sign-up, with data stored locally in your browser.

- One-place logging of dose, site, and symptoms with automatic syncing of web-entered doses/sites/symptoms to the app
- Push-notification reminders (iOS) keep dosing consistent
- Weight and symptom trend charts (iOS) reveal real-world patterns
- Exportable PDF/CSV progress reports for clinician discussions
- No dosing recommendations — only organization

How these capabilities map to common evaluation criteria:

- Capture average weight loss: Pepio centralizes weight entries and dose history so you can calculate average change over time. Trials typically show mean weight loss of about 10–15% for semaglutide over 68–104 weeks and about 15–22% for tirzepatide over ~72 weeks. Your personal results vary by dose, adherence, and tolerability ([Scientific article on caloric reduction with GLP-1 therapy](https://www.sciencedirect.com/science/article/pii/S0002916525002400)).

- Time to change: Date-stamped logs reveal when appetite or weight shifted after a dose change. GLP-1s reduce daily caloric intake by 16–39% in trials, so tracking intake timing and weight can help reveal early trends ([Scientific article on caloric reduction with GLP-1 therapy](https://www.sciencedirect.com/science/article/pii/S0002916525002400)).

- Adherence and dosing flexibility: Push-notification reminders (iOS) and simple logs help maintain consistent shot schedules. Reminders can help users stay on schedule.

- Side-effect logging: Time‑stamped symptom notes combined with weight and symptom trend charts (iOS), exportable PDF/CSV, and automatic syncing of web-entered doses/sites/symptoms make it easier to link side effects to dose timing.

- Injection-site rotation: Recording injection sites and using injection-site rotation memory (iOS) removes guesswork and reduces repeated-site use. Clear site history supports safer routine management without clinical interpretation.

- Clinician visit support: Exportable progress reports let you bring tidy, dated records to appointments. Digital engagement with tracking tools is associated with an extra 2–3% body-weight loss versus medication alone, so using a tracker can meaningfully inform follow-ups ([Impact of Digital Engagement on Weight Loss Outcomes](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997532/)).

Pepio’s approach helps you turn scattered notes into a single, reviewable routine. Learn more about Pepio’s approach to tracking GLP-1 routines and how organized records can support weight-loss decisions with your clinician. Pepio is for organization and self-tracking only. Pepio does not provide medical advice, dosing recommendations, or treatment guidance. Always follow the instructions from your clinician, prescriber, pharmacist, or medication label.

## Option 2 – Mounjaro (Tirzepatide) Overview

Major trials of tirzepatide in obesity and diabetes programs reported substantial weight reductions. Many SURPASS and SURMOUNT cohorts showed average body-weight losses above 15% in some dose groups, according to trial reports and comparative analyses ([JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080); [Journal of Clinical Medicine Research](https://jocmr.elmerjournals.com/jocmr/article/view/6231)). These results position tirzepatide as highly effective on average, though outcomes vary by dose and population.

Dosing is typically once-weekly with gradual titration to the target dose. Trials used a weekly injection cadence with stepwise increases to improve tolerability ([JAMA Internal Medicine](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080)). That schedule affects time to peak effect and flexibility for individual users.

Common side effects in studies included nausea, diarrhea, and reduced appetite. Most side effects were transient and dose-related in trial reports ([Journal of Clinical Medicine Research](https://jocmr.elmerjournals.com/jocmr/article/view/6231)). Real-world coverage has also noted faster weight changes compared with some GLP‑1s in news summaries ([Los Angeles Times](https://www.latimes.com/science/story/2024-07-08/mounjaro-bests-ozempic-for-weight-loss)).

Injection-site care matters because tirzepatide is given subcutaneously once weekly. Rotating sites helps reduce local irritation and preserves tissue health. Tracking injection sites and dates supports safe rotation and cleaner records.

From an evaluation perspective: efficacy rates are high in trials; time to effect is moderate, often weeks to months; dosing follows weekly titration; side effects are common but usually manageable; injection-site needs require rotation; and tracking utility is strong for routine management.

Pepio helps you keep dose dates, site rotation notes, and symptom logs together so you can review patterns over time. Users who log injections and symptoms tend to bring clearer notes to clinician visits. Learn more about Pepio’s approach to organizing GLP‑1 and peptide routines while following your clinician’s instructions. This summary reports trial outcomes only. It does not provide dosing advice. Always follow guidance from your clinician or pharmacist.

## Option 3 – Ozempic (Semaglutide) Overview

For readers searching "Ozempic weight loss outcomes clinical trials," the STEP program provides the clearest evidence. The STEP 1 trial found a mean 14.9% weight reduction after 68 weeks. Seventy percent of participants lost ≥10% body weight and 50% lost ≥15% ([NEJM STEP 1](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)). The STEP 5 two‑year trial reported a mean 15.3% weight loss with semaglutide versus 2.4% with placebo at 104 weeks ([Nature Medicine STEP 5](https://www.nature.com/articles/s41591-022-02026-4)).

Serious adverse events were similar between groups in STEP 5. The trial reported 4.5% for semaglutide versus 3.8% for placebo. Common side effects included nausea, constipation, and occasional vomiting ([Nature Medicine STEP 5](https://www.nature.com/articles/s41591-022-02026-4)). Broader reviews also note semaglutide’s consistent weight‑loss signal across populations ([Cureus review](https://www.cureus.com/articles/282731-efficacy-of-different-doses-and-forms-of-the-glp-1-receptor-agonist-semaglutide-in-weight-reduction-among-non-diabetic-obese-or-overweight-populations)).

How this maps to key evaluation criteria:
- Efficacy: STEP trials show large mean percent reductions and high rates of ≥10% and ≥15% thresholds.
- Timeline: Meaningful weight loss appears by months and continues across 68–104 weeks in trials.
- Dosing convenience: Once‑weekly subcutaneous dosing follows an established titration schedule in trials ([NEJM STEP 1](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)).
- Side effects: Gastrointestinal effects are the most common and should be tracked.
- Injection‑site flexibility: Once‑weekly injections allow multiple site options.
- Tracking needs: Dose history, symptoms, injection sites, and weight trends matter for long‑term review.

Pepio helps people keep that routine organized by recording shot dates, injection sites, symptoms, and weight trends. Teams using Pepio experience clearer dose histories and easier symptom review before clinician visits. To explore practical tracking, learn more about Pepio’s approach to GLP‑1 routine organization. **Disclaimer:** Pepio is for organization and self‑tracking only. Follow your clinician’s instructions for dosing and medical care.

## Side‑by‑Side Comparison and Use‑Case Recommendations

Pepio sits alongside clinical options in a practical way. Below is a compact, scannable comparison across six common criteria, followed by short use‑case recommendations.

| Criterion | Pepio | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|---|
| Efficacy (trial mean % weight loss) | Pepio — helps you track personal percent change over time. | Mounjaro — trial averages around 15% or more in SURMOUNT weight‑loss trials ([SURMOUNT-1 et al.](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)). | Ozempic — semaglutide trials report roughly 10–15% weight loss in STEP‑style studies ([NEJM STEP trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)). |
| Time to measurable change | Pepio — logs weekly weights to surface 4–6 week trends. | Mounjaro — some trials show earlier and larger change by 12 weeks versus semaglutide (see comparative analyses and trial reports, e.g., [JAMA Internal Medicine review](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080)). | Ozempic — measurable changes often appear by 4–6 weeks, with larger effects through 24–36 weeks ([STEP‑style data](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)). |
| Dosing flexibility & convenience | Pepio — records schedules and reminders for any weekly routine. | Mounjaro — once‑weekly dosing with clinician‑led titration supported in trials; follow your prescriber’s instructions (see the FDA prescribing information). | Ozempic — once‑weekly with an established titration path commonly used in practice (see the FDA label and STEP trial schedules, e.g., [Wegovy/Ozempic prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215833s000lbl.pdf)). |
| Side‑effect profile | Pepio — lets you log nausea, diarrhea, constipation, and fatigue for pattern review. | Mounjaro — GI side effects are common, including nausea and diarrhea, noted in comparative trials ([JAMA Internal Medicine review](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080)). | Ozempic — GI effects like nausea and constipation are commonly reported in semaglutide studies ([review/PMCID](https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/)). |
| Injection‑site needs | Pepio — tracks site rotation to reduce repeated use of the same area. | Mounjaro — weekly injections require conscious rotation and record keeping. | Ozempic — weekly injections also benefit from site rotation and logging. |
| Tracking & clinician prep | Pepio — creates sharable dose, symptom, and weight summaries for visits. | Mounjaro & Ozempic — both have robust trial data; personal tracking helps put trial averages into your real‑world context (see SURMOUNT weight‑loss trials and STEP semaglutide studies). | See Pepio column for tracking benefits; clinical trial averages are useful context but individual experience varies. |

- Pepio is best if you want to collect clear, date‑stamped dose, symptom, and weight records to discuss with your clinician.

- Consider Mounjaro if trial‑level reports and your prescriber prioritize larger average percent loss and you accept a potentially stronger GI profile.

- Consider Ozempic if you prefer established semaglutide evidence and a well‑known titration path guided by your clinician. Individual choice depends on your medical history and clinician guidance. Use these comparisons as practical context, not clinical advice. Learn more about Pepio’s approach to routine tracking and how organized records can help your next clinician conversation.

Trial data generally favor tirzepatide (Mounjaro) for larger average weight loss in the SURMOUNT program and related publications ([SURMOUNT‑1 et al.](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)). Individual choice still depends on tolerance, access, and cost ([KFF Health Tracking Poll, May 2024](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)). Track your doses, weight, and symptoms so you can review trends with your clinician. Pepio helps keep that data organized and shareable for appointments. To log shots, symptoms, and weight, learn more about Pepio.

Pepio is for organization and self‑tracking only and does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow instructions from your clinician, prescriber, pharmacist, medication label, or care team.